Drug Development in Academia
The SPARK Approach
SPARK Mission

Partnership between university and industry to:

• **Advance** promising research discoveries to the clinic and commercial sector

• **Educate** faculty, fellows and graduate students on the translational process (discovery and development) for therapeutics and diagnostics

• **Innovate** efficient and cost-effective approaches to discovery and development
Translating Academic Discoveries

THE GAP: valley of death

An IDEA

Target Identification

Screening, Hit Identification

Lead Identification

Lead Optimization

Pre-Clinical

Clinical trials
Phase 1 & Phase 2

Phase 3

Big Pharma

Biotech

Drug

Academia

SPARK
SPARK Selection Criteria

Proposed projects must:

1) Address an unmet need
2) Utilize a novel approach
3) Have the potential to advance to commercial sector or clinical testing with 2-3 years of SPARK support

SPARK accepts proposals for any clinical indication. Special consideration is given to orphan disease and areas historically neglected by industry (e.g., pediatric, tropical).
SPARK Provides

- **Education**: Year-long seminar on important topics in drug and diagnostics development
  - Alternates with project updates
  - Topics range from assay development to commercialization and are taught by expert advisors
- **Advising**: Access to specialized knowledge from our dedicated group of volunteer advisors, in the form of 1:1 advising and project updates to whole group
- **Mentorship**: Each team is assigned a project manager within SPARK to help identify needs and lower roadblocks. PMs also act as matchmakers for possible investors or collaborators
- **Funding**: Money is tied to achievement of milestones and held in a central account (avg: $50K/project/year)
SPARK Program Statistics

- Founded in 2006
- 83 projects supported (as of 2014; “SPARK 8”)
- Plus 9 student-led programs
  - CSB 240 A&B: Drug Discovery and Development Course

19% of projects were in global health
14% orphan indications
33% child and maternal health indications
How SPARK measures success

With SPARK participation, we hope projects will:

• Educate faculty and trainees on the process of drug development
  - More-informed to work in or collaborate with industry
  - Make translational research second-nature

• License to an existing company or funded start-up

and/or

• Enter a clinical trial (therapeutic) or validation study with human samples (diagnostic)
SPARK Success Metrics

Outcomes: SPARK Graduated Projects

- Licensed + in clinic: 12
- Licensed - not in clinic: 8
- Unlicensed in clinic: 10
- Unlicensed: 12
- Scooped: 1
- Failed POC/disengage: 8

51 graduates
The SPARK Book

‘A Practical Guide to Drug Development in Academia: The SPARK Approach’

“I think this book should be required reading for any scientists in academia who plan to engage in translation of discoveries into the clinic. The authors have really been there, and they have done their homework. The chapters are not only informative, they are infused with the kind of advice that only comes from living this endeavor. Highly recommended”
- Janet Woodcock, Director, Center for Drug Evaluation and Research, FDA.

• Available for sale on Springer or Amazon websites (note: SPARK/editors/authors receive no royalties on book sales)
Contact Us

website: sparkmed.stanford.edu
email: sparkmed@stanford.edu

Co-Directors:
Kevin Grimes &
Daria Mochly-Rosen

Program Managers:
Emily Egeler & Kanad Das

Admin:
Kathy Johnson